Loading patent…
OwnerAli Amara, Fernando Arenzana-Seisdedos +2inventors
InventorsAli Amara, Fernando Arenzana-Seisdedos, Philippe Despres, Jean-Louis Virelizier
Estimating the term…
The present invention relates to methods and compositions for preventing or treating diseases of a mammal, including viral infections, wherein at least one symptom of the disease is mediated at least in part by the binding of an effector molecule to a DC-SIGN receptor present on cells of the mammal to be treated. The invention also provides methods of identifying compositions, wherein the compositions are useful for treating mammalian diseases, including viral infections, for which at least one symptom of the disease is mediated at least in part by the specific binding of an effector molecule to a DC-SIGN receptor present on the cells that express the DC-SIGN receptor, belonging to the mammal to be treated. The invention further relates to compositions and methods for targeting subject molecules to cells that express the DC-SIGN receptor.
Use of an amount of a DC-SIGN modulator sufficient to substantially modulate the binding of an effector molecule to a DC-SIGN receptor for the preparation of a medicament for preventing or treating a disease of a mammal, wherein at least one symptom of the disease is mediated at least in part by the binding of the effector molecule to the DC-SIGN receptor of the mammal to be treated.
Use of an amount of a DC-SIGN blocker sufficient to substantially inhibit the binding of an effector molecule to a DC-SIGN receptor for the preparation of a medicament for preventing or treating a disease of a mammal, wherein at least one symptom of the disease is mediated at least in part by the binding of the effector molecule to the DC-SIGN receptor of the mammal to be treated.
Use of an amount of a DC-SIGN modulator sufficient to substantially modulate the binding of a viral effector molecule to a DC-SIGN receptor for the preparation of a medicament for preventing or treating a viral infection of a mammal, wherein the viral infection is mediated at least in part by the binding of the viral effector molecule to the DC-SIGN receptor of the mammal to be treated.
Use of an amount of a DC-SIGN blocker sufficient to substantially inhibit the binding of a viral effector molecule to a DC-SIGN receptor for the preparation of a medicament for preventing or treating a viral infection of a mammal, wherein the viral infection is mediated at least in part by the binding of the viral effector molecule to the DC-SIGN receptor of the mammal to be treated.
Use of an amount of a DC-SIGN modulator sufficient to substantially modulate the binding of HIV or SIV to a DC-SIGN receptor present on dendritic cells of a human or a simian for the preparation of a medicament for preventing or treating an HIV or a SIV infection of said human or said simian.
Use of an amount of a DC-SIGN blocker sufficient to substantially inhibit the binding of HIV or SIV to a DC-SIGN receptor present on dendritic cells of a human or a simian for the preparation of a medicament for preventing or treating an HIV or a SIV infection of said human or said simian.
Use of an amount of a DC-SIGN modulator sufficient to substantially modulate the binding of ICAM-3 present on T cells of a mammal with DC-SIGN receptor present on dendritic cells of the mammal for the preparation of a medicament for preventing or treating inflammation in said mammal caused by specific binding of ICAM-3 present on T cells of the mammal with DC-SIGN receptor present on dendritic cells of the mammal.
Use of an amount of a DC-SIGN blocker sufficient to substantially inhibit the binding of ICAM-3 present on T cells of a mammal with DC-SIGN receptor present on dendritic cells of the mammal for the preparation of a medicament for preventing or treating inflammation in said mammal caused by specific binding of ICAM-3 present on T cells of the mammal with DC-SIGN receptor present on dendritic cells of the mammal.
A pharmaceutical composition comprising:
A method of identifying a DC-SIGN modulator, wherein the method comprises:
A method of identifying a DC-SIGN blocker, wherein the method comprises:
A method of targeting a subject molecule to a cell expressing a DC-SIGN receptor by exposing the cell to a targeting complex, wherein the targeting complex comprises a subject molecule and a DC-SIGN blocker, wherein the exposure is under conditions which allow the DC-SIGN blocker to bind to DC-SIGN on the cell expressing the DC-SIGN receptor, thereby targeting the subject molecule to the cell expressing a DC-SIGN receptor.
A pharmaceutical composition comprising:
Dependencies are inferred from the claim text.